Monovalency unleashes the full therapeutic potential of the DN-30 anti-Met antibody - Wikidata - awgldk - TriplyDB

Monovalency unleashes the full therapeutic potential of the DN-30 anti-Met antibody

Monovalency unleashes the full therapeutic potential of the DN-30 anti-Met antibody

http://www.wikidata.org/entity/Q34285473

about

Agonist antibodies activating the Met receptor protect cardiomyoblasts from cobalt chloride-induced apoptosis and autophagy Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent Four individually druggable MET hotspots mediate HGF-driven tumor progression.A novel bispecific c-MET/PD-1 antibody with therapeutic potential in solid cancer.Non-agonistic bivalent antibodies that promote c-MET degradation and inhibit tumor growth and others specific for tumor related c-MET.Anti-MET immunoPET for non-small cell lung cancer using novel fully human antibody fragments Aptamers Binding to c-Met Inhibiting Tumor Cell Migration Improving target cell specificity using a novel monovalent bispecific IgG design Biochemical and pharmacological characterization of human c-Met neutralizing monoclonal antibody CE-355621 Anti-c-Met antibodies recognising a temperature sensitive epitope, inhibit cell growth MET inhibition overcomes radiation resistance of glioblastoma stem-like cells.Progress of antibody-based inhibitors of the HGF-cMET axis in cancer therapy.Role of MetMAb (OA-5D5) in c-MET active lung malignancies.Targeting the oncogenic Met receptor by antibodies and gene therapy.Bi-specific aptamers mediating tumor cell lysis.Inhibition of ligand-independent constitutive activation of the Met oncogenic receptor by the engineered chemically-modified antibody DN30.TNF-α promotes invasive growth through the MET signaling pathway.Increase of MET gene copy number confers resistance to a monovalent MET antibody and establishes drug dependence.An 'in-cell trial' to assess the efficacy of a monovalent anti-MET antibody as monotherapy and in association with standard cytotoxics Targeted therapy by gene transfer of a monovalent antibody fragment against the Met oncogenic receptor.Cbl-independent degradation of Met: ways to avoid agonism of bivalent Met-targeting antibody.Tumor Inhibitory Effect of IRCR201, a Novel Cross-Reactive c-Met Antibody Targeting the PSI Domain.The MET Oncogene as a Therapeutical Target in Cancer Invasive Growth.Monovalent IgG4 molecules: immunoglobulin Fc mutations that result in a monomeric structure.Dual Constant Domain-Fab: A novel strategy to improve half-life and potency of a Met therapeutic antibody.Attenuation of MET-mediated migration and invasion in hepatocellular carcinoma cells by SOCS1.MET-targeting antibody (emibetuzumab) and kinase inhibitor (merestinib) as single agent or in combination in a cancer model bearing MET exon 14 skipping.Population pharmacokinetic analysis from phase I and phase II studies of the humanized monovalent antibody, onartuzumab (MetMAb), in patients with advanced solid tumors.Recent Progress and Advances in HGF/MET-Targeted Therapeutic Agents for Cancer Treatment.Monoclonal Antibodies against the MET/HGF Receptor and Its Ligand: Multitask Tools with Applications from Basic Research to Therapy.Status of Agents Targeting the HGF/c-Met Axis in Lung Cancer

P2860

Q24294894-C0C827A6-063F-4354-95E7-D9DF34E75F55 Q27679191-3005B938-A3DF-4835-AFD7-B936766AF7D0 Q30581656-04E61B35-FB18-4CD7-8057-C1047FA40D04 Q33710008-86452D1E-FF57-4047-97C3-131C80085ED6 Q34236834-7CD32887-8104-4952-BC50-095E3F57ED04 Q34459696-5F17DA46-76A2-4489-A55D-AE5BEF1C2D35 Q35866739-20BE7FA4-2F9A-42DA-A9F9-E1533B4277A7 Q36213090-25B214FD-EF1C-475B-8FE6-FA917A0CED04 Q36411841-86F76FB4-6EEF-498D-A0AC-65C0954A74B7 Q37138521-56500CA5-F37B-41DE-9C13-D52AEA72CCED Q37458626-947764F9-F12C-46B7-9A4E-6643968BFF20 Q37739477-961AD887-0FAB-4D63-85CF-2CB972EBD596 Q37952015-F60852E2-9972-4E4E-89FB-DADADF13F80A Q38216590-AF93D987-EE10-48DB-B032-39571D60843E Q38335529-953002E7-8C2B-4918-8613-F41BB9807FD4 Q38859217-1F444AB5-AFB4-40F2-A22D-7A05FD41938F Q38948786-24471651-AEA6-4BD6-B2F6-5455ADF7B76E Q38976616-62223A4D-BD5B-4460-B038-3F12EF20004A Q39037450-5990DD82-05FC-4EA3-9528-6466F92A0C16 Q39098665-A71EA6F2-7B77-4162-9B18-9FD3D42B2D3B Q39233148-E80DDC66-6255-4517-8A55-B62E4E97E77C Q41660598-4046390B-C0D7-4834-88AF-F7A626C1B19B Q41954928-91C4E668-FEB9-497E-90BF-16002DF5222B Q41968539-DD378972-B427-477C-8DC4-D62E5E1C0A86 Q42282846-71AED592-58C1-4037-AB05-D84D015A0C23 Q42695141-39314E4E-22DB-4FD5-AF65-4A7CEEC486E1 Q47393684-9D2ED252-2D91-49D7-8CF7-B20ACA260B96 Q47842123-F0F23621-DF3F-41C8-933A-44AC2A59D2BC Q50985091-3E33D334-0E82-498F-986C-BD4E9F28EC2A Q53789447-E6390B30-8DEE-4CEF-8433-15ADE96767A2 Q58726253-A450A411-6061-45AE-AA84-AB8465A46B6A

P2860

Monovalency unleashes the full therapeutic potential of the DN-30 anti-Met antibody

http://www.wikidata.org/entity/Q34285473

description

2010 nî lūn-bûn

@nan

2010 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Monovalency unleashes the full therapeutic potential of the DN-30 anti-Met antibody

@ast

Monovalency unleashes the full therapeutic potential of the DN-30 anti-Met antibody

@en

Monovalency unleashes the full therapeutic potential of the DN-30 anti-Met antibody

@nl

type

label

Monovalency unleashes the full therapeutic potential of the DN-30 anti-Met antibody

@ast

Monovalency unleashes the full therapeutic potential of the DN-30 anti-Met antibody

@en

Monovalency unleashes the full therapeutic potential of the DN-30 anti-Met antibody

@nl

prefLabel

Monovalency unleashes the full therapeutic potential of the DN-30 anti-Met antibody

@ast

Monovalency unleashes the full therapeutic potential of the DN-30 anti-Met antibody

@en

Monovalency unleashes the full therapeutic potential of the DN-30 anti-Met antibody

@nl

P1433

Q34285473-D527B5C9-0138-420E-9FAE-F3637203FFDA

P1476

Q34285473-6F077AB8-D089-4952-A5B0-A3D09CDB5206

P2093

Q34285473-6BD0DC7D-69B8-452C-A253-0440F29B9382

Q34285473-78C40C3D-29A3-48AD-96FB-47061828A4D1

Q34285473-8585C6D0-E443-4576-8631-E83E8747DA11

Q34285473-A170D3F4-8F64-4C54-B4C5-EABB565956F6

Q34285473-A2376076-8DFE-4196-A59E-42E7CC880D58

Q34285473-C6F8078F-2788-4EE3-9BCD-B551B59CA212

Q34285473-DDD0469E-C224-4443-9749-5C0A0BD7C708

P2860

Q34285473-0686A4F0-CCAF-4A6C-8A87-3BC30032B31B

Q34285473-0981C0F5-523A-4426-B358-5C0EB8D94A3A

Q34285473-0CC30A1E-5B96-4341-B005-580DCED8D59D

Q34285473-20222EB7-D6C4-48C2-95DD-19BE5AC95A8E

Q34285473-22AE403C-A5BF-4603-98DA-1BE1CC40BA84

Q34285473-308001F7-A6F4-438F-AC33-50F038526760

Q34285473-4766C7CB-E384-4B39-BCC4-56147E6F8139

Q34285473-49162128-1F06-46CB-8DA8-140840BD2EBF

Q34285473-4EF6E2C0-9D12-44C2-AA19-0F03E93A193A

Q34285473-5BB724A1-1750-4E32-AF39-3A20CC9EDE2F

P304

Q34285473-2EB4207C-5FFC-477F-83F2-56F67CED781A

P31

Q34285473-2D6197C0-717E-4D68-9F6D-9479445C17D4

P356

Q34285473-646DC49F-6E09-4DB1-9980-30E7A8234A54

P407

Q34285473-335F507A-41E6-44F0-8AE3-68FB6E942F0A

P433

Q34285473-E2119B43-E613-43EC-8793-F094CC5A377A

P478

Q34285473-F6FC826E-E6BF-49E5-A2DD-9C08FD65B5E5

P50

Q34285473-58BDFBA6-4FEE-4334-9D52-D6B3D10088CF

Q34285473-8BFD37EE-510B-49B9-B25A-E2C682CB60EB

Q34285473-AD457382-2DCD-4090-AE92-835D2996697B

P577

Q34285473-1C09F014-5E31-41C4-898B-1C448D9FF4BA

P698

Q34285473-6D18C2FC-B687-46FC-99C9-35DBB36DAD0D

P921

Q34285473-2289DEED-5A1D-404D-96FB-F300B96D9DD0

P932

Q34285473-8BCFF436-5E7A-4414-8DC9-1093146A8C3D

P356

JBC.M110.134031

P1433

Journal of Biological Chemistry

P1476

Monovalency unleashes the full therapeutic potential of the DN-30 anti-Met antibody

@en

P2093

Cristina Chiriaco

http://www.w3.org/2001/XMLSchema#string

Fiorella Petronzelli

http://www.w3.org/2001/XMLSchema#string

Giovanni Pacchiana

http://www.w3.org/2001/XMLSchema#string

Maria C Stella

http://www.w3.org/2001/XMLSchema#string

Maria Galluzzo

http://www.w3.org/2001/XMLSchema#string

Paolo Carminati

http://www.w3.org/2001/XMLSchema#string

Paolo Michieli

http://www.w3.org/2001/XMLSchema#string

P2860

Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752

Ab-induced ectodomain shedding mediates hepatocyte growth factor receptor down-regulation and hampers biological activity

Met, metastasis, motility and more

Invasive growth: a MET-driven genetic programme for cancer and stem cells

Targeting the tumor and its microenvironment by a dual-function decoy Met receptor

Developmental roles of HGF/SF and its receptor, the c-Met tyrosine kinase

High-throughput antibody production.

Invasive growth: from development to metastasis

Scatter-factor and semaphorin receptors: cell signalling for invasive growth.

PEGylated antibodies and antibody fragments for improved therapy: a review.

P304

36149-36157

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1074/JBC.M110.134031

http://www.w3.org/2001/XMLSchema#string

P407

P433

46

http://www.w3.org/2001/XMLSchema#string

P478

285

http://www.w3.org/2001/XMLSchema#string

P50

Paolo M. Comoglio

P577

2010-09-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20833723

http://www.w3.org/2001/XMLSchema#string

P921

P932

2975237

http://www.w3.org/2001/XMLSchema#string